Skip to content

The Effect of a Combination of Orange- and Pomegranate Actives on Physical Fitness in Elderly People

The Effect of a Combination of Orange- and Pomegranate Actives on Physical Fitness in Elderly People

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03781999
Enrollment
37
Registered
2018-12-20
Start date
2018-06-25
Completion date
2019-01-17
Last updated
2019-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fitness

Keywords

Performance, Polyphenols, Nutrition, Sports

Brief summary

The primary objective of this study is to determine the effect of daily supplementation of a combined orange- and pomegranate extract for a period of 4 weeks on physical fitness compared to placebo. In this crossover study, participants will daily receive either a placebo or Actiful®, a supplement containing 500 mg orange extract and 200 mg pomegranate actives, for 4 weeks followed by a wash-out period of 4 to 8 weeks. Subsequently, the second intervention period of 4 weeks (active product or placebo) will take place. The product and placebo will be supplied in capsules that participants can ingest with a glas of water (daily, prior to breakfast).

Detailed description

Dietary habits and physical activity are two important components of a healthy lifestyle. Targeted nutritional interventions may improve health and stimulate physical activity. Both orange extracts and pomegranate concentrate have been shown to exert beneficial effects on health and exercise performance. However, the effects of a combination of the two extracts on exercise and physical activity have not been investigated yet. It is expected that this combination may be an effective dietary way to improve exercise performance, physical activity in the free-living state, and quality of life in a middle aged population.

Interventions

DIETARY_SUPPLEMENTActiful

supplement containing 500 mg orange extract and 200 mg pomegranate actives

OTHERPlacebo

Maltodextrin

Sponsors

BioActor
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* 60 - 75 years old * non smoking * BMI 18 -28 kg/m²

Exclusion criteria

* Allergy to test product/placebo or citrus fruits * BMI lower than 18 or higher than 28 * Recent muscle injury in less than one month before the start of the study * Inability to perform the fitness tests * Medical conditions that might influence outcome measure or participant safety during testing, including but not limited to: severe cardiovascular disease, cancer, Parkinson's disease. To be decided by PI. * High blood pressure (systolic ≥ 140 mmHg, diastolic ≥ 90 mmHg) * Use of medication that may interfere with the study results, use of beta-blockers * Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study * Abuse of products; alcohol (\> 20 alcoholic units per week) and drugs

Design outcomes

Primary

MeasureTime frameDescription
6 Minute Walking Test0-4-8-12 weeksParticipants have to walk for 6 minutes, as fast as possible. Total distance will be measured.

Secondary

MeasureTime frameDescription
Senior Fitness test0-4-8-12 weeksFitness tests to see if Actiful improves physical activity level
Daily physical activity measured by accelerometers0-4-8-12 weeksAccelerometer is worn for 7 days prior to each testing day
Quality of life questionnaire - WHOQOL-1000-4-8-12 weeksParticipants will be asked to fill out the WHOQOL-100 questionnaire to determine quality of life. Scale from 1-5 (disagree-agree)
Concentration of blood marker TAC0-4-8-12 weeksTotal antioxidant capacity measurement in plasma

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026